Dr. Agarwal on the STAMPEDE and LATITUDE Trials for Prostate Cancer

Neeraj Agarwal, MD
Published: Thursday, Jun 22, 2017



Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.

The phase III STAMPEDE and LATITUDE trials have changed the standard of care for patients with newly diagnosed metastatic hormone-sensitive prostate cancer, states Agarwal.

Both trials combined abiraterone acetate (Zytiga) plus prednisone plus standard androgen deprivation therapy, explains Agarwal. Given the data from the trial, abiraterone plus prednisone is the new standard of care for the patient population.
 


Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the STAMPEDE and LATITUDE trials for patients with prostate cancer.

The phase III STAMPEDE and LATITUDE trials have changed the standard of care for patients with newly diagnosed metastatic hormone-sensitive prostate cancer, states Agarwal.

Both trials combined abiraterone acetate (Zytiga) plus prednisone plus standard androgen deprivation therapy, explains Agarwal. Given the data from the trial, abiraterone plus prednisone is the new standard of care for the patient population.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual International Congress of Oncology Pathology™: Towards Harmonization of Pathology and Oncology StandardsAug 30, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x